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Abstract
Background/Aim: Hepatitis C virus (HCV) is a major threat as almost 3% of the world’s population (350 million
individual) and 10% of the Pakistani population is chronically infected with this virus. RNA interference (RNAi), a
sequence-specific degradation process of RNA, has potential to be used as a powerful alternative molecular
therapeutic approach in spite of the current therapy of interferon-a and ribavirin against HCV which has limited
efficiency. HCV structural gene E2 is mainly involved in viral cell entry via attachment with the host cell surface
receptors i.e., CD81 tetraspanin, low density lipoprotein receptor (LDLR), scavenger receptor class B type 1 (SR-B1),
and Claudin1 (CLDN1). Considering the importance of HCV E2 gene and cellular receptors in virus infection and
silencing effects of RNAi, the current study was designed to target the cellular and viral factors as new therapeutic
options in limiting HCV infection.
Results: In this study the potential of siRNAs to inhibit HCV-3a replication in serum-infected Huh-7 cells was
investigated by combined treatment of siRNAs against the HCV E2 gene and HCV cellular receptors (CD81 and
LDLR), which resulted in a significant decrease in HCV viral copy number.
Conclusion: From the current study it is concluded that the combined RNAi-mediated silencing of HCV E2 and
HCV receptors is important for the development of effective siRNA-based therapeutic option against HCV-3a.
Keywords: HCV, siRNA, HCV receptors, HCV envelope genes and viral titer
Introduction
HCV infection is a major health problem with nearly
10% chronically infected population in Pakistan and 350
million people worldwide [1,2]. About 75% of patients
achieve no therapeutic benefit from the present combi-
nation therapy with pegylated interferon a (PEG-IFN-a)
and ribavirin mainly depending upon HCV genotype,
whereas in 40-60% patients chronic infection is mainly
associated with liver cirrhosis and steatosis leading to
hepatocellular carcinoma (HCC) [3-5]. In Pakistan the
major HCV genotype is 3a followed by 3b and 1a, with
a strong correlation between chronic HCV infection and
HCC in Pakistan associated with genotype 3a [6,7].
There is a desperate need to develop more efficient and
better therapeutic alternative for treatment of HCV
infections.
Due to the absence of suitable animal model and com-
petent in vitro cell culture system the mechanism of HCV
cell entry was unrevealed after a long time. Recently, dif-
ferent groups have studied HCV replication in serum
infected liver cell lines which mimics the naturally occur-
ring HCV virions biology and kinetics of HCV infection in
humans liver cells [8-11]. HCV envelop glycoproteins E1
and E2 are involved in HCV entry, fusion and defense
against neutralization by envelop-specific host antibodies
[12-18]. E2 glycoprotein works as a key component in
interaction between the virus and its major cellular recep-
tors i.e., CD81, SR-BI and CLDN1 [15-17]. CD81 is a main
HCV cell surface receptor, whereas additional role is
played by the scavenger receptor class B type I (SRBI) and
the low-density-lipoproteins receptor (LDLR) [19-22].
LDLR is potentially involved in the uptake of lipoprotein-
associated HCV into hepatocytes as serum fraction
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tein (VLDL), which are involved in binding to the LDL
receptor as a possible mechanism of HCV cell entry
[23-25]. Hence, HCV envelope glycoprotein and cellular
receptors is good target for the development of antiviral
molecules that could block HCV entry.
Being a RNA virus HCV is highly susceptible to RNA
interference (RNAi) induced by small interfering RNA
(siRNA), which is a sequence specific gene silencing
mechanism [26-28]. siRNAs can be used as a potential
therapeutic agent against HCV because HCV replication
takes place in the cytoplasm of liver cells without inte-
gration into the host genome. siRNA directed against
HCV genotype 1a and 1b has been shown to effectively
block the replication of viral replicons in Huh-7-derived
cell lines [29-35]. In our previous study, the develop-
ment of siRNA targeting envelope proteins of the local
HCV-3a genotype showed that these genes are crucial
for viral entry providing better choice for developing a
rational antiviral strategy against HCV [36]. Several
investigators have reported the inhibition of HCV RNA
by targeting structural and non structural genes of HCV
and cellular genes by using siRNAs in combination
[33,36-38]. In this report, we investigated the effect of
siRNA induced silencing of receptor genes and HCV E2
on viral load of HCV followed by a combined effect
which showed a significantly decreased viral RNA.
Results
Cellular genes CD81 and LDLR are functionally involved
in HCV entry. Our previous results also show that
sequence specific siRNAs against each receptor signifi-
cantly inhibit the expression of their respective genes of
receptors CD81, LDLR, SRBI and CLDN1 (data sub-
mitted for publication). Keeping all these in view, we
used in-vitro transcribed siRNA against HCV E2 gene
and cellular receptors CD81and LDLR and observed the
effect of silencing of these receptors on viral titer. Pre-
viously, we have successfully inhibited HCV by E2 siR-
NAs [36], from that study we selected the best one for
this study. The effect on viral titer was analyzed by
silencing each receptor and E2 gene individually and
then in combination of siRNAs against two receptors
and E2 gene simultaneously. To evaluate the role of
HCV E2 gene and HCV receptors in HCV infection and
HCV pathogenesis, Huh-7 cells were infected with
HCV-3a serum with or without siRNAs against HCV
receptors CD81, LDLR and HCV E2-3a gene for 48hrs
and viral loads were quantified by Real Time PCR.
Results showed a decrease of 62%, 45%, with HCV
receptor siRNA CD-81, LDL, 60%, and 72% with HCV
E2 siRNA, (E2si873), respectively in viral load. A signifi-
cant suppression of HCV RNA (84% and 78%) was
observed with the combination of both siRNAs against
HCV E2 gene, E2 siRNA (E2si873) and HCV receptor
genes CD81(siCD81-B), LDLR (siLDLR) (Figure 1).
Furthermore, the effect on protein expression inhibi-
tion of HCV structural gene E2, receptor genes CD81
and LDLR on the expression of viral protein were deter-
mine by western blot analysis using specific antibodies.
Huh-7 cell lysates infected with HCV serum of genotype
3a with or without siRNAs (100nM each) against HCV
receptors CD81, LDLR and HCV E2-3a gene for 48hrs
were separated through SDS PAGE and treated with
specific antibodies of each gene. Results indicate the sig-
nificant inhibition of protein expression of CD81 and E2
3a, when combination of siRNA (E2si873 +siCD81-B)
were used as compare to individual siRNA against
CD81 and HCV E2 (Figure 2A). These results show the
reduce total cellular viral protein expression due to the
low expression of HCV envelop protein as well as CD81
receptor protein simultaneously. Similarly, western blot-
ting results indicate the significant inhibition of expres-
sion of LDLR and E2 3a, when combination of siRNA
(E2si873 +siLDLR) were used as compare to individual
siRNA against LDLR and HCV E2 (Figure 2B), which
also show the reduce total cellular viral protein expres-
sion due to the low expression of HCV envelop protein
as well as LDLR receptor protein simultaneously.
Discussion
HCV entry into hepatocytes, a multistep process
mediated by HCV envelop glycoprotein E1 and E2 and
several cell surface receptors, is first step of virus life
Figure 1 Graphical representation of combine effect of siRNA
against HCV E2 gene and HCV receptors gene CD-81, LDLR on
viral titer in serum infected Huh-7 cells. For Viral titer in Huh-7
cells treated with scrambled siRNAs (Sc) and CD-81 siRNA (siCD81-
B), LDL siRNA (siLDLR), E2 siRNA (E2si873) either alone or in
combinations and incubated for 6 hrs before adding HCV-3a sera
(Ser 3a). HCV RNA levels were quantified by Real Time PCR. Three
independent experiments with triplicate determinations were
performed. Error bars indicate, mean S.D *p < 0.01 verses Ser3a.
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major targets for immunopreventive and therapeutic
strategies [39-41]. The cell surface receptors mainly
include tetraspanin protein CD81, SR-BI, LDLR and
CLDN1 a tight junction protein [17,20-22,42]. HCV
envelop protein E2 posses’ glycosylation sites which
interact directly with these cell surface receptors. As in
our previous study, here too we utilized serum infected
Huh-7 cell culture model to evaluate the effect of
siRNA separately and in combination against HCV
structural gene and receptor genes on viral entry by
quantifying the viral titer in siRNA-treated and non-
treated serum-infected Huh-7 cells.
RNAi is an exciting new therapeutic technology pro-
posed to be used in treatment of viral diseases. HCV is
an attractive target for RNAi therapy as its genome is a
(+) sense single stranded RNA that functions as both
the viral messenger RNA and template for RNA replica-
tion via negative strand intermediate. Previously it has
been reported that cellular genes functionally involved
in HCV entry like CD81, LDLR, SR-BI and CLDN1 also
serve as potential targets for RNAi. Several reports
showed potent RNAi against HCV genes and cellular
receptors activity to reduce the HCV infection in which
expression of HCV was distinctly inhibit HCV serum
infection (30%-90%) [11,36,42-45]. In our current pro-
ject, we utilized siRNAs to silence the expression of
HCV cellular receptors and E2 gene to block the HCV
entry in serum derived HCV infected Huh-7 cell culture
model and analyze its effect on viral load. HCV infection
pathway employs enhancement in expression of cell sur-
face receptors that may facilitates to increase viral load.
In account of these, we knock down the expression of
host cell surface HCV receptors by using siRNA to
block HCV entry, against each receptor gene separately
and in combination of siRNA against two receptors
gene in Huh-7 cells which were further infected with
HCV serum of genotype 3a and observed the viral titer
by detection of 5’UTR of viral copies by Real Time PCR
in cells from 3
rd day post infection. Our results indicate
significant decrease in HCV viral load by 67% and 58%
due to the silencing of HCV receptor CD81 (33 fold)
and LDLR (42 fold) respectively when compared to con-
trol (S3a), (Figure 1). Since, LDLR is important for
HCV-E1-pseudotype infectivity, whereas CD81 deter-
mines the infectivity of HCV-E2-pseudotype virus, the
silencing effect of siRNAs against selected HCV infec-
tion host cellular proteins has been evaluated to reduce
viral titer significantly. Thus use of combinations of siR-
NAs against both the virus and host genes involve in
HCV infection are likely to be a potent approach in the
treatment of chronic hepatitis C due to their additive
HCV RNA inhibition effects. Moreover, different studies
exhibit the feasibility of targeting host cellular factors
involved in infection, as they are not prone to muta-
tions, as potential targets for siRNA therapy. Henry and
colleagues [46] targeted the IRES, NS5B, and host cell
receptor CD81 by triple shRNA expression vector which
concurrently reduced the HCV replication, CD81
expression, and E2 binding. Targeting multiple sites of
the HCV genome and host factors involved in HCV
infection are a realistic and valid approach aimed at pre-
venting the virus from developing resistance.
In correspondence to the latest reports, we also inves-
tigated the down regulation of viral titer by silencing the
expressions of HCV envelop gene alone using HCV E2
specific siRNA (E2si873) and in combination with the
silencing of CD81 or LDLR gene expression using
siCD81-B, siLDLR in Huh-7 cells which were further
infected HCV 3a serum. Our findings showed a signifi-
cant decrease in HCV viral titer up to 67% and 58%,
with siCD81-B, siLDLR and 72% with HCV E2 siRNA
(E2si873), respectively in the Huh-7 cells. A significant
suppression of HCV RNA (84% and 78%) was observed
with the combination of both siRNAs against HCV E2
gene, E2 siRNA (E2si873), and CD81, LDLR siRNAs
(Figure 1). Likewise, cell lysates from HCV serum
infected Huh-7 cells were examined by western blot
Figure 2 Protein expression analysis of HCV E2 gene and HCV
receptors genes by using siRNA alone and in combination
against HCV gene E2 and HCV receptor genes CD81, LDLR.
Protein isolated from Huh-7 cells treated with single and
combination of siRNA against HCV E2 gene and receptor CD81 and
LDLR genes and incubated for 6 hrs before adding HCV-3a sera (Ser
3a) for 48 hrs. Protein levels were quantified by western blot
analysis using specific antibodies of CD81, LDLR, E2 and GAPDH. A)
Silencing of CD81 gene and HCV 3a E2 gene alone and in
combination using specific antibodies showing reduction at protein
expression level. B) Silencing of LDLR gene and HCV 3a E2 gene
alone and in combination, using specific antibodies showing
reduction at protein expression level. Protein levels for GAPDH gene
are also shown as internal control and scramble siRNA (Sc) as siRNA
control.
Jahan et al. Virology Journal 2011, 8:295
http://www.virologyj.com/content/8/1/295
Page 3 of 6analysis using CD81, LDLR and HCV-E2 specific antibo-
dies. Our results showed considerable decreased in the
protein levels of CD81, LDLR and HCV-E2 in transi-
ently transfected siCD81-B, siLDLR and E2si873 siR-
NAs, whereas combination of siCD81-B + E2si873 and
E2si873 + siLDLR resulted in a more significant
decrease of CD81, LDLR protein expression that ulti-
mately reduced the protein level of HCV-E2 which
depicts the reduced entry of HCV, hence lessen the
HCV infection (Figure 2).
In summary, our data showed that CD81 and LDL
specific siRNAs not only reduced their gene expression
respectively but also reduced viral titer in siRNA treated
cells confirming their role in HCV infection; combina-
tion of these siRNA (siCD81-B, siLDLR) with E2 effec-
tive siRNA (E2si873) showed dramatic reduction of
HCV entry. Use of siRNA to inhibit the HCV E2 protein
or HCV receptor protein expression alone or in combi-
nation could be helpful in reduction of HCV entry. In
addition, we propose the use of combination siRNAs
against HCV gene with host genes which could inhibit
HCV entry better than separately used siRNA.
Materials and Methods
Source of samples
The local HCV-3a patient’s serum samples used in this
investigation were obtained from the CAMB (Center for
Applied Molecular Biology) diagnostic laboratory,
Lahore, Pakistan after quantification and genotype deter-
mination. Serum samples were stored at -80°C prior to
RNA extraction for cloning and viral inoculation experi-
ments. Patient’s written consent and approval for this
study was obtained from institutional ethics committee.
Designing and synthesis of siRNA
Designing and synthesis of siRNA were done as we have
described earlier [36]. siRNA oligonucleotides were
designed to express RNAi mechanism against host HCV
receptors (LDLR and CD81) and E2 region of HCV-3a
genome using the Ambion’s siRNA design tool http://
www.ambion.com/techlib/misc/siRNA_finder.html after
sequencing of local HCV-3a patient’ss e r u ms a m p l e s
(Table 1). The designed siRNAs (cellular genes HCV
receptors, HCV-3a E2 and control Scrambled) were
synthesized using Silencer siRNA construction kit
according to the manufacturer’s instruction (Ambion,
USA).
Viral inoculation and co-transfection with siRNA
Huh-7 cell line was kindly provided by Dr. Zafar Nawaz
(University of Miami, USA) and maintained in Dulbec-
co’s modified eagle medium (DMEM) supplemented
with 100 μg/ml penicillin; streptomycin and 10% fetal
bovine serum referred as complete medium (Sigma
Aldrich, USA) at 37°C with 5% CO2. The medium was
renewed every 3 day and passaged every 4-5 days. Huh-
7 cell line was used to establish the in vitro replication
of HCV genotype 3a. A similar protocol was used for
viral inoculation as described by earlier [36,45]. For
these experiments high viral titer > 1 × 10
8 IU/ml con-
taining serum from HCV-3a patient was used as princi-
ple inoculum. Huh-7 cells were maintained in 6-well
culture plates to semi-confluence, washed twice with
serum-free medium then inoculated with 500 μl( 5×
10
7IU/well) viral load of HCV-3a sera and 500 μls e r u m
free media. Cells were maintained overnight at 37°C in
5% CO2. Next day, the adherent cells were washed three
times with 1 × PBS, complete medium was added and
incubation was continued for 48hrs. Cells were har-
vested and assessed for the presence of viral RNA quan-
titatively by Real Time PCR. To analyze the effect of
siRNA on HCV infection, serum infected Huh-7 cells
were seeded after three days of infection in 24-well
plates and grown to 80% confluence with 2ml medium.
The cells were transfected with or without 40 μM/well
cellular receptors CD81, LDL-R and E2 siRNAs alone or
in combination using Lipofectamine™ 2000 (Invitrogen
Life technologies, CA) according to the manufacturer’s
protocol.
Viral load quantification
Cells were harvested for viral load determination using
Gentra RNA isolation kit (Gentra System Pennsylvania,
USA) according to the manufacturer’si n s t r u c t i o n s .F o r
viral quantification Sacace HCV quantitative analysis kit
(Sacace Biotechnologies Caserta, Italy) was used. Briefly,
10 μl of extracted viral RNA was mixed with an internal
control provided by Sacace HCV Real TM Quant kit
and subjected to viral quantification using Real Time
PCR SmartCycler II system (Cepheid Sunnyvale, USA).
Total RNA isolation and gene expression analysis
Total RNA from HCV serum infected and non-infected
cells was isolated using TRIzol reagent (Invitrogen life
technologies, CA), 24 hrs and 48hrs post-transfection.
To analyze the effect of siRNA on envelope gene
Table 1
Name Sequences
Scramble-antisense AACCTGCATACGCGACTCGACCCTGTCTC
Scramble-sense AAGTCGAGTCGCGTATGCAGGCCTGTCTC
CD81-B antisense AAGATGCCTACATAGAAGGTGCCTGTCTC
CD81-B sense AACACCTTCTATGTAGGCATCCCTGTCTC
LDL antisense AAATGCATCTCCTACAAGTGGCCTGTCTC
LDL sense AACCACTTGTAGGAGATGCATCCTGTCTC
E2si873-antisense AACAACTGAGCTTGCCATACTCCTGTCTC
E2si873-sense AAAGTATGGCAAGCTCAGTTGCCTGTCTC
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RNA using Superscript III cDNA synthesis kit (Invitro-
gen life technologies, CA) and semi-quantitative RT-
PCR was done using primers of HCV receptors, E2
genes and GAPDH as control. Quantitative Real Time
PCR was carried out using Real Time ABI 7500 system
(Applied Biosystems Inc, USA) with SYBR Green mix
(Fermentas International Inc, Canada) as we have
described earlier [36]. The relative gene expression ana-
lysis was carried out by the SDS 3.1 software (Applied
Biosystems Inc, USA). Each individual experiment was
performed in triplicate.
Western blotting
To determine the effect of siRNAs on protein expression
levels HCV receptors CD81 and LDL-R and E2, in HCV
serum infected cells, cells were lysed using ProteoJET
mammalian cell lysis reagent (Fermentas, Canada). Equal
amounts of total proteins were subjected to electrophor-
esis on 12% SDS-PAGE and electrophoretically trans-
ferred to a nitrocellulose membrane according to the
manufacturer’s protocol (Bio-Rad, CA). After blocking
non-specific binding sites with 5% skimmed milk, blots
were incubated with primary monoclonal antibodies spe-
cific to HCV cellular receptors like CD81 and LDL-R,
HCV E2 and GAPDH genes (Santa Cruz Biotechnology
Inc, USA) and secondary Horseradish peroxidase-conju-
gated anti-goat anti-mouse antibody (Sigma Aldrich,
USA). The protein expressions were evaluated using che-
miluminescence’s detection kit (Sigma Aldrich, USA).
Statistical analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
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